相似文献
1
Accrual, Publication Bias, and the Coronavirus in 2020.
Oncologist. 2020 Jul;25(7):e1001-e1002. doi: 10.1634/theoncologist.2020-0455. Epub 2020 May 29.
2
Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial.
JCO Glob Oncol. 2020 Apr;6:585-588. doi: 10.1200/GO.20.00072.
3
Rethinking Clinical Trials Reform During the COVID-19 Pandemic.
JAMA Oncol. 2020 Sep 1;6(9):1327-1329. doi: 10.1001/jamaoncol.2020.3142.
4
The Virtual Match: A New Approach to Celebrating Students During Social Distancing Due to COVID-19.
Acad Med. 2020 Nov;95(11):e8-e9. doi: 10.1097/ACM.0000000000003605.
5
The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing.
Nat Biotechnol. 2020 Sep;38(9):1021-1024. doi: 10.1038/s41587-020-0655-4.
6
Presenting symptoms of COVID-19 in children: a meta-analysis of published studies.
Br J Anaesth. 2020 Sep;125(3):e330-e332. doi: 10.1016/j.bja.2020.05.026. Epub 2020 May 31.
7
Questions asked through two examples of dilemmas of publication ethics in the process of COVID-19.
Med Oncol. 2020 Aug 24;37(10):86. doi: 10.1007/s12032-020-01411-8.
8
[Covid-19, the Société française du cancer (SFC) and the BulletinduCancer].
Bull Cancer. 2020 Apr;107(4):393-394. doi: 10.1016/j.bulcan.2020.03.004.
9
Digitalized Adaptation of Oncology Trials during and after COVID-19.
Cancer Cell. 2020 Aug 10;38(2):148-149. doi: 10.1016/j.ccell.2020.06.018. Epub 2020 Jul 6.
10
Oncology Practice During the COVID-19 Pandemic.
JAMA. 2020 May 26;323(20):2005-2006. doi: 10.1001/jama.2020.6236.
引用本文的文献
1
Barriers to publishing early phase clinical trials: the oncologists' perspective.
Oncologist. 2025 Apr 4;30(4). doi: 10.1093/oncolo/oyaf042.
2
Early phase trials: the perils of nonpublication.
Oncologist. 2025 Apr 4;30(4). doi: 10.1093/oncolo/oyaf041.
3
Journal of Optometry in Emerging Sources Citation Index (ESCI) and peer-review process during COVID-19 pandemic.
J Optom. 2020 Oct-Dec;13(4):213-215. doi: 10.1016/j.optom.2020.06.003.
本文引用的文献
1
Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
Oncologist. 2020 Jul;25(7):562-e1012. doi: 10.1634/theoncologist.2020-0034. Epub 2020 Feb 12.
2
Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.
Lancet. 2020 Feb 1;395(10221):361-369. doi: 10.1016/S0140-6736(19)33220-9. Epub 2020 Jan 17.
3
Publish or Perish v2.
Oncologist. 2019 Jun;24(6):723-724. doi: 10.1634/theoncologist.2019-0319. Epub 2019 May 7.
4
Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database.
Invest New Drugs. 2018 Oct;36(5):933-938. doi: 10.1007/s10637-017-0549-6. Epub 2017 Dec 13.
5
Comprehensive analysis of the clinical immuno-oncology landscape.
Ann Oncol. 2018 Jan 1;29(1):84-91. doi: 10.1093/annonc/mdx755.
6
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.
7
Trial Reporting in ClinicalTrials.gov - The Final Rule.
N Engl J Med. 2016 Nov 17;375(20):1998-2004. doi: 10.1056/NEJMsr1611785. Epub 2016 Sep 16.
8
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.
Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.
9
Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
J Natl Cancer Inst. 2015 Dec 29;108(2). doi: 10.1093/jnci/djv324. Print 2016 Feb.
10
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Oncologist. 2014 Oct;19(10):e5-11. doi: 10.1634/theoncologist.2014-0241. Epub 2014 Aug 28.
Zotero 插件